Abstract:Objecitve To investigate the expression of long non-coding RNA (lncRNA) FOXD3-AS1 in serum of patients with multiple myeloma (MM) to analyze its relationship with clinicopathological features and prognosis. Methods Eighty-two patients with MM were selected as the research group, and 70 healthy persons were served as the control group at the same time.The real-time fluorescence quantitative PCR (qRT-PCR) was used to detect the expression of lncRNA FOXD3-AS1 in peripheral blood of all subjects.Receiver operating characteristics (ROC) curve was used to analyze the value of lncRNA FOXD3-AS1 in the diagnosis of multiple myeloma and its relationships with clinical parameters and therapeutic effect of MM patients.COX regression was used to analyze the prognostic risk factors MM patients. Results Compared with control group, the expression level of lncRNA FOXD3-AS1 in MM patients statistically increased (P<0.05) and was related to clinical stage and grade of osteopathy (P<0.05). ROC analysis showed that the predicted AUC value of lncRNA FOXD3-AS1 for MM was 0.837 (95%CI :0.816-0.851) with an optimal cut-off value of 1.27. The clinical efficacy in patients with high expression of lncRNA FOXD3-AS1 was significantly lower than that of patients with low expression of lncRNA FOXD3-AS1 (P<0.05).During one year of follow-up, 25 patients died with a mortality rate of 30.48%. Multivariate COX analysis showed that clinical stage, grade of osteopathy and expression of lncRNA FOXD3-AS1 were the independent factors influencing the prognosis of MM patients.The mortality rate in patients with high expression of lncRNA FOXD3-AS1 was significantly higher than that of patients with low expression (38.78% vs 18.18%, χ²=3.946, P=0.047). Conclusion High expression of lnc RNA FOXD3-AS1 is an independent risk factor for survival in MM patients.